Hospitalization Outcomes of Patients with Type 2 Diabetes Mellitus Complicated with Diabetic Ketoacidosis

• Published in: The Israel Medical Association journal 2024-10, Vol.26 (9), p.566
• Main Authors: Keler, Maly, Vlasov, Pavel, Elkan, Matan, Koren, Shlomit, Koren, Ronit
• Format: Article
• Language: English
• Subjects: Adult; Aged; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Ketoacidosis - epidemiology; Diabetic Ketoacidosis - therapy; Female; Hospital Mortality; Hospitalization - statistics & numerical data; Humans; Israel - epidemiology; Length of Stay - statistics & numerical data; Male; Middle Aged; Patient Readmission - statistics & numerical data; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
• ISSN: 1565-1088

Diabetic ketoacidosis (DKA) poses a significant medical emergency in both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) patients. Recent attention has focused on the emergence of euglycemic DKA associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. To understand the epidemiology and outcomes of DKA, particularly in T2DM patients. We conducted a retrospective cohort analysis of 204 patients admitted with DKA to Shamir Medical Center (2013-2021). We assessed demographics, clinical characteristics, and outcomes. Patients were stratified by diabetes type and SGLT2 inhibitor treatment status. Among the 204 patients with DKA, 38.2% had T2DM. Patients with T2DM exhibited older age, higher co-morbidity burden, and greater prevalence of microvascular complications compared to T1DM patients. Mortality rates were notably higher among T2DM patients, despite similar DKA severity at presentation, including in-hospital mortality rates of 6.4% vs. 0%, P < 0.05, and 90-day mortality rates of 7.7% vs. 0%, P < 0.05. T2DM was independently associated with adverse hospitalization outcomes, including a composite of rehospitalization, prolonged hospital stays, and mortality (odds ratio 2.68, 95% confidence interval 1.302-5.557). SGLT2 inhibitor treatment did not affect hospitalization outcomes of patients with T2DM. Our findings underscore the importance of recognizing DKA as a substantial complication in diabetic patients, particularly those with T2DM. Vigilance in management, adherence to DKA guidelines, and awareness of triggers such as SGLT2 inhibitors are crucial for improving outcomes in this population.